Zobrazeno 1 - 10
of 110
pro vyhledávání: '"William F C Rigby"'
Publikováno v:
PLoS ONE, Vol 17, Iss 6, p e0270393 (2022)
Patients with cystic fibrosis (CF) often suffer recurrent bronchial bacterial infections that lead to deterioration of lung function over time. The infections in CF patients are often due to S. aureus and P. aeruginosa that colonize the airways. Sign
Externí odkaz:
https://doaj.org/article/3aa7734af1634366830e69ed7aa5f1c3
Publikováno v:
PLoS Pathogens, Vol 17, Iss 3, p e1009338 (2021)
Host defense proteins (HDPs), aka defensins, are a key part of the innate immune system that functions by inserting into the bacterial membranes to form pores to kill invading and colonizing microorganisms. To ensure survival, microorganism such as S
Externí odkaz:
https://doaj.org/article/7d0e317d0d8d464fbcbf55ab1e6f9745
Autor:
Jomkuan Theprungsirikul, Sladjana Skopelja-Gardner, Ashley S. Burns, Rachel M. Wierzbicki, William F. C. Rigby
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Chronic Pseudomonas aeruginosa infection mysteriously occurs in the airways of patients with cystic fibrosis (CF), bronchiectasis (BE), and chronic obstructive pulmonary disease (COPD) in the absence of neutrophil dysfunction or neutropenia and is st
Externí odkaz:
https://doaj.org/article/8f52417a94ca460f972305c27be5664e
Autor:
Sladjana Skopelja-Gardner, Jomkuan Theprungsirikul, Kimberley A. Lewis, John H. Hammond, Kyrsten M. Carlson, Haley F. Hazlett, Amanda Nymon, Dao Nguyen, Brent L. Berwin, Deborah A. Hogan, William F. C. Rigby
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Pseudomonas aeruginosa is the most prevalent opportunistic pathogen in the airways of cystic fibrosis (CF) patients. The pulmonary disorder is characterized by recurrent microbial infections and an exaggerated host inflammatory immune response led pr
Externí odkaz:
https://doaj.org/article/7c7b8ed6e6fb4f949d33cd66b1cb4924
Autor:
Vivekanand Tiwari, William F. C. Rigby
Publikováno v:
ACR Open Rheumatology, Vol 4, Iss 2, Pp 119-122 (2022)
Autor:
Peter Nash, Philip G. Conaghan, Eduardo Mysler, Jayeshkumar Patel, Yoshiya Tanaka, Gerd R Burmester, Stanley Cohen, Pankaj Patel, Rochelle Sun, Roy Fleischmann, Jianzhong Liu, T. Shaw, William F. C. Rigby, Keith A. Betts
Publikováno v:
Rheumatology and Therapy. 9:191-206
Rheumatoid arthritis (RA) is a chronic autoimmune disease requiring long-term treatment. Upadacitinib (UPA), a Janus kinase (JAK) inhibitor, is a new treatment for RA. The benefit–risk profile of a medication is best understood by evaluating the nu
Autor:
Neelufar Mozaffarian, Daniel W. T Ching, Jonathan Kay, Z. Yin, Rene Westhovens, Chantal Tasset, John S. Sundy, Robert Landewé, Gerd R Burmester, Tatsuya Atsumi, William Stohl, Franziska Matzkies, Désirée van der Heijde, William F. C. Rigby, Osvaldo D. Messina, Arvind Chopra, Ying Guo, Beatrix Bartok, Angelika Jahreis
Publikováno v:
Annals of the Rheumatic Diseases
Objectives To investigate efficacy and safety of the Janus kinase-1 inhibitor filgotinib in patients with active rheumatoid arthritis (RA) with limited or no prior methotrexate (MTX) exposure. Methods This 52-week, phase 3, multicentre, double-blind
Autor:
Edith T. Zemanick, Jomkuan Theprungsirikul, Alix Ashare, Sladjana Skopelja-Gardner, John P. Clancy, William F. C. Rigby, R.E. Meagher
Publikováno v:
Journal of Cystic Fibrosis. 19:196-202
Background Pseudomonas aeruginosa accounts for ~80% of cystic fibrosis (CF) airway infection. It shows a remarkable correlation with presence of autoantibody to bactericidal/permeability-increasing protein (BPI), which is not understood. In this stud
Autor:
Keith S. Kanik, Ricardo Rojo, Huifeng Yun, Thijs Hendrikx, Kevin L. Winthrop, Pinaki Biswas, Jeffrey R. Curtis, Gerd R Burmester, Sujatha Menon, William F. C. Rigby, Niki Palmetto, Valderílio Feijó Azevedo, Oliver FitzGerald, Cunshan Wang, Thomas R. Jones
Publikováno v:
Drug Safety
Introduction Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). Objective Our objective was to compare the incidence rates (IRs) of adverse events in tofacitinib clinical trials and real-world observational
Autor:
Katherine J. Sessions, Sladjana Skopelja-Gardner, William F. C. Rigby, Jomkuan Theprungsirikul, Rachel M. Wierzbicki
Publikováno v:
J Immunol
Bactericidal/permeability-increasing protein (BPI) plays a major role in innate immunity through the ability of the N-terminal domain (NTD) to bind LPS, mediate cytotoxicity, and block LPS-induced inflammation. The C-terminal domain mediates phagocyt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29ab62f8150730e9b6ca41960a9d1086
https://europepmc.org/articles/PMC8354091/
https://europepmc.org/articles/PMC8354091/